Frontlight ResearchEarly access
Active, not recruitingPhase 4
A randomized, two-armed, single-blind, parallel, active controlled, and non-inferiority clinical trial to Compare Efficacy and Safety of anti TNF-alfa biosimilar molecules to the originators in children with active Juvenile Idiopathic Arthritis
Key facts
- Who runs it
- Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
- Where
- Italy17 sites in 1 countryChoose a country to see its sites
- Status
- Active, not recruiting
- Phase
- Phase 4
- People taking part
- 290 people, planned
- Started
- 1 Oct 2022
- Expected to end
- 12 Jul 2027
- Type of study
- Interventional
- Record updated
- 17 April 2025
Who can take part
- Age
- Up to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Children with a diagnosis of JIA according to the ILAR criteria, candidate to treatment with anti-TNF alpha drugs (etanercept or adalimumab) as per the approved label indication and per treating physician/family decision, classified as per ILAR criteria in: Oligoarthritis; Rheumatoid factor negative polyarthritis; Rheumatoid factor positive polyarthritis; Psoriatic arthritis; Enthesitis-related arthritis
- Moderate to high disease activity despite methotrexate treatment for at least 3 months
- Age 2 to <18 years at time of enrolment
- For Etanercept, only patients eligible for receiving authorized biosimilar formulations according to the Summary of Product Characteristics (SmPC), i.e. with the proper weight range, will be enrolled: since etanercept biosimilar formulations are available only with fix doses (25 mg and 50 mg), only patients, with age < 18 years old at the time of enrolment, weighted >30 and < 32 kg or subjects > 62 kg could be enrolled
- Ability to comply with the entire study procedures, ability to communicate meaningfully with the investigational staff to be applied to the parents and/or patients, as appropriate
- Duly executed, written, informed consent obtained from the patient’s parents
- For sexually active participants, compliance in undertaking highly effective contraception methods throughout the study
Who cannot take part
- Purified protein derivative (PPD) skin test or QuantiFERON-TB positive patients (with no active disease) are excluded from the study unless it is documented by a specialist that the patient has been adequately treated for TB and can start treatment with a biologic agent, based on the medical judgment of the study investigator and / or an infectious disease specialist
- Any live attenuated vaccine within 4 weeks prior to the baseline visit, such as varicella-zoster, oral polio, measle, mumps or rubella vaccines and throughout the study. Killed or inactive vaccine may be permitted based on the investigator’s judgment
- Prior or current history of malignancy, including lymphoproliferative diseases, other than adequately-treated carcinoma in-situ of the cervix, nonmetastatic squamous cell, or basal cell carcinoma of the skin, within 5 years prior to the baseline visit
- Sepsis or risk of sepsis, active infections including chronic or local infections
- Moderate to severe heart failure (NYHA class III/IV)
- A history of COVID-19 infection or vaccination does not exclude participation in the trial if real-time reverse transcription polymerase chain reaction (RT-PCR) confirm the absence of viral RNA in patient specimens
- Hypersensitivity to the active substance or to any of the excipients
- Positive serologic findings of hepatitis B or C
- Active tuberculosis TB or a history of incompletely treated TB
- Suspected extrapulmonary TB infection
- Prior or current history of other significant concomitant illness(es) that, according to the Investigator’s judgment, would adversely affect the patient’s participation in the study. These include, but are not limited to, cardiovascular, renal, neurological disorder (including demyelinating disease), active infectious diseases, endocrinological, gastrointestinal, hepatobiliary, metabolic, pulmonary (e.g. severe asthma, cystic fibrosis), nonmalignant lymphoproliferative diseases, other lymphatic disease(s), autoimmune disease, psychiatric disorders, history of inflammatory bowel disease, severe diverticulitis, or previous gastrointestinal perforation, uncontrolled diabetes mellitus, defined as glycosylated hemoglobin (HbA1c) ≥ 9% at the screening visit
- Abnormalities in laboratory values: white blood cell count < 3,000/mm3, a platelet count < 50,000/mm3, levels of serum glutamic oxaloacetic transaminase/asparagine aminotransferase (SGOT/AST) or serum glutamic pyruvic transaminase/alanine aminotransferase (SGPT/ALT) above the upper limit of normal according to the local lab reference, creatinine levels above the upper limit of normal according to the local lab reference or eGFR < 60 ml/min/1.73 m2 calculated according with bedside Schwartz equation, chronic proteinuria or hematuria (2–4/4 on dipstick on 2 consecutive tests)
- Children with systemic JIA according to ILAR criteria
- For Etanercept, patients with a weight range different from the indications reported in the Summary of Product Characteristics of the biosimilar formulations will not be enrolled. If, during the study, the weight falls outside the indicated ranges for taking biosimilars, the subject will be withdrawn from the study
- Ongoing treatment in the screening phase with any other second-line agents (except methotrexate) or intravenous immunoglobulin
- Patients at high risk of contracting TB, such as close contact with individual with active or latent TB
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study is aimed to evaluate, through a pragmatic trial, safety and efficacy of switching from the adalimumab and etanercept originator molecules versus their biosimilar competitors and vice-versa in children with JIA in clinical remission on anti-TNF medication.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 17 April 2025